Deng Feng: The Situation Is Hard To Shake Up The Enthusiasm Of Medical Investment, VC Should Be Arranged Before The Big Wave Arrives.

In June this year, burning stone medicine was listed on NASDAQ. This 2014 investment brought more than 100 times the book return to the aurora venture.

In the past 2012-2014 years, the aurora borealis has been sequenced in the field of gene sequencing. This means that when the first year of genetic testing came in 2015, Aurora has completed its investment card in the field of gene sequencing.

"The most important thing for early investment is to see opportunities before big waves come." Deng Feng, founder of the aurora initiative, believes that early VC should ask the team to think in terms of entrepreneurs.

Aurora Deng Feng. Data map

The six partners of aurora are responsible for different investment tracks. Deng Feng is not only the founder of the aurora venture capital, but also the director of the health care board.

In his view, medical investment is a long and wide track. That is to say, this is a field worthy of 20 or more years of systematic layout. The external market volatility in the short term will not be hindered by the long-term development of the industry.

In the recent two interview, Deng Feng said that whether the Sino US trade friction or the new crown epidemic situation will not shake investors' optimism on the medical sector.

In the medical field, the momentum of increasing investment in the field of health care will become inevitable after the outbreak of the new crown. From the perspective of capital market's enthusiasm for medical enterprises, taking stone burning medicine as an example, "we are also worried about the epidemic and the stock market. At the moment, Wall Street investors do not have the recognition and enthusiasm to reduce fuel consumption because of these."

Aurora has entered the field of medical investment for more than 10 years. More than 50 medical projects have covered five subdivision tracks of biomedicine, in vitro diagnostics, medical devices, medical services and E-Health.

Its forward-looking layout is not only in the field of gene sequencing, but also in the field of innovative drugs, which began in 2015 before the accelerated approval of innovative drugs. In January this year, as the "fifth set of standards" listed on the "Chuang Chuang board", zhe pharmaceutical, the first investment in northern light, was invested in 2017.

Deng Feng believes that the value of venture capital is to invest funds and resources to advanced productive forces, which is the reason why VC can accelerate the development of excellent companies and emerging industries.

"Early VC represents the technology and mode of advanced productivity." In his view, foresight is the essential quality of VC investors. For a good investment organization, "it is too late to reinvest the draught".